Selank

At a glance

Overview

Selank is a modified peptide related to tuftsin, an endogenous immune-associated sequence. It appears in discussions of anxiety, stress, and cognition, but those labels span different scientific questions. The available human literature includes relatively small studies in selected clinical populations. A study comparing two active treatments can be informative, yet without a placebo group it may not separate drug effects from expectation, symptom fluctuation, and other care. Claims of a universally effective, non-sedating, dependence-free anxiolytic go beyond what these reports can establish. The compound and its acetate form also require attention to formulation and characterization.

Supporting sources [1] [2] [3]

How it works

Research has explored enkephalin metabolism, gene-expression changes, and pathways related to inhibitory neurotransmission. These are proposed or experimentally observed effects, not proof of one fully established clinical mechanism. A blood enkephalin marker does not directly measure brain anxiety circuits. Mechanistic observations may guide future studies, but the relationship between exposure, symptom relief, and adverse effects remains insufficiently characterized.

Supporting sources [1] [2] [3]

The small comparative study

A 2008 report included 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 medazepam. The authors reported similar anxiolytic effects and examined serum enkephalin activity. The small sample, mixed diagnostic population, and active-comparator design limit certainty. Similar scores in one study do not establish equivalence to standard treatments across broader populations.

Supporting sources [1]

Laboratory results remain a separate evidence tier

An original rat study examined expression of genes involved in neurotransmission after Selank exposure. Such work helps formulate hypotheses about action but cannot demonstrate clinical benefit or freedom from dependence. Molecular changes can be complex and may have different consequences depending on dose, tissue, route, and disease context.

Supporting sources [2]

Formulation and regulatory limits

FDA identifies safety-information gaps for compounded Selank acetate and possible immunogenicity related to aggregation or impurities. This concern is about insufficient characterization, not a measured incidence of harm. A compounding discussion or a research sale does not create an approved U.S. anxiety indication.

Supporting sources [3]

Frequently asked questions

Does similar performance to medazepam prove that Selank is equivalent?
No. One small active-comparator study cannot establish broad clinical equivalence, particularly without a placebo group and a robust equivalence design.

Does the available evidence establish no dependence or interaction risk?
No. Those claims require specific, adequately designed human studies. Small anxiety reports and laboratory gene-expression changes do not answer every safety question.

Supporting sources [1] [2] [3]